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lation, and that switching to the PO protocol signiﬁcantly
decreased the per day acyclovir cost, as well as the per-
centage of the patients’ stay on IV acyclovir therapy 
relative to PO [$11.33 vs. $19.37 (p-value: 0.00001) and
33% vs. 89% (p-value: 0.00001), respectively]. A sensi-
tivity analysis showed that if the infection rate had been
greater, the changes in these variables would have still
been signiﬁcant. Adjusting for clinically interesting 
variables reinforced these results. However, subgroup
analysis showed that the results were non-signiﬁcant 
for two groups: (multiple myeloma and solid tumor).
CONCLUSIONS: Oral acyclovir is a clinically safe and
cost-saving method compared to IV acyclovir for HSV
prophylaxis before a BMT.
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OBJECTIVES: Previous analyses have shown that antivi-
ral therapy for herpes zoster is economically reasonable,
however much of the effect comes from moderation of
postherpetic neuralgia (PHN), particularly in the elderly.
Effective medications to ameliorate PHN are now avail-
able, but their impact on antiviral cost-effectiveness 
is unclear. METHODS: We modiﬁed our previous zoster/
PHN model to consider PHN therapy in 70 year-olds. We
used this model to estimate the cost-effectiveness of
antiviral therapy in the presence of effective PHN therapy.
A societal perspective was taken, using reference case rec-
ommendations of the Panel on Cost-Effectiveness in
Health and Medicine. We assumed that antivirals lessened
acute zoster symptoms and decreased PHN duration, but
not its likelihood or severity. PHN therapy side effects
were not considered, biasing the analysis against antivi-
rals. Mild and severe acute zoster scenarios were consid-
ered, with utilities of 0.9 and 0.7 respectively on a 0 =
death and 1 = perfect health scale. RESULTS: If effective
PHN therapy is not available, antiviral therapy costs
$47,300 per quality-adjusted life year (QALY) gained for
mild acute zoster and $18,800/QALY for severe acute
zoster. When gabapentin is the PHN therapy considered
(34.5% pain relief, average wholesale price $197/mo.),
antiviral therapy of mild zoster costs $40,600/QALY and
severe acute zoster treatment cost $11,300/QALY. For
mild zoster, antivirals plus PHN therapy cost more per
QALY than antivirals alone when PHN therapy pain
relief is >60%, costing $64,700 with 100% relief. For
severe zoster, antivirals plus PHN therapy cost less than
antivirals alone even when PHN relief is 100% (costing
$14,700/QALY). Other PHN therapies show similar
effects. CONCLUSIONS: PHN therapy has little impact
(except for mild improvement) on the cost-effectiveness
of antiviral therapy for herpes zoster, due to relatively 
low reported levels of pain relief (<40%) as well as 
longer PHN duration and loss of acute zoster relief when
antivirals are not used.
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OBJECTIVES: This analysis compared, from a managed
care perspective, the economic impact of using
lopinavir/ritonavir- vs. nelﬁnavir-based highly active 
antiretroviral treatment (HAART) in antiretroviral
(ART)-naïve HIV patients. METHODS: The data from a
randomized phase III study of lopinavir/ritonavir + 2
nucleoside reverse transcriptase inhibitors (NRTIs) vs.
nelﬁnavir + 2 NRTIs (Protocol ABT-M98-863) in treat-
ing ARV-naïve HIV patients were reanalyzed from an
effectiveness (vs. efﬁcacy) perspective to estimate drop-
out and treatment failure rates, assuming a failure thresh-
old of 400 copies HIV RNA/mL. Patient care protocols
based on clinical guidelines, literature review, and physi-
cian input were used to model the cost of managing
patients who maintained virologic response or who expe-
rienced virologic failure. For patients with PI resistance
the replacement regimen was 2 protease inhibitors 
(PI) + 2 NRTIs and for those without PI resistance the
regimen was PI + 2 NRTIs. RESULTS: At 60 weeks,
lopinavir/ritonavir was superior to nelﬁnavir in the pro-
portion of patients responding to therapy or experiencing
a loss of virologic response with drug resistance. The
model projected that fewer lopinavir/ritonavir patients
would require change of therapy or additional monitor-
ing, and that patients initiating ART with lopinavir/riton-
avir would incur less costs (total savings of $1553), which
can be attributed to lower ART ($25,601 vs. $26,825),
drug resistance testing ($97 vs. $179), and other costs
($728 vs. $975). The superiority of lopinavir/ritonavir
was robust to sensitivity analysis on changes in viral load
thresholds for treatment failure (savings of $1264 for a
threshold of 1000 copies/mL and $1022 for a threshold
of 5000 copies/mL) and alternative replacement regimens
(savings of $782 for PI + 2 NRTIs and $1,217 for PI + 2
NRTIs + 1 non-NRTI). CONCLUSIONS: Based on this
analysis, lopinavir/ritonavir appears to be clinically and
economically preferable to nelﬁnavir as the PI cornerstone
of HAART in ART-naïve HIV-infected patients.
